Drugs & Targets EMA validates application for Opdivo + Yervoy and Opdivo + chemotherapy in recurrent or metastatic ESCC indication September 03, 2021Vol.47 No.32
Drugs & Targets Sabatolimab receives orphan drug designation from the European Commission for myelodysplastic syndromes September 03, 2021Vol.47 No.32
Drugs & Targets Foundation Medicine and Epic to streamline access to genomic testing for precision cancer care September 03, 2021Vol.47 No.32
Drugs & Targets Werewolf Therapeutics, Merck collaborate on WTX-124 INDUKINE Program September 03, 2021Vol.47 No.32
Drugs & TargetsFree Opdivo receives EC approval in Esophageal/GEJ indication August 06, 2021Vol.47 No.31
Drugs & TargetsFree FDA grants Priority Review to Tecentriq as adjuvant treatment in NSCLC indication August 06, 2021Vol.47 No.31
Drugs & TargetsFree Cabometyx sNDA receives FDA priority review for previously treated radioactive iodine-refractory differentiated thyroid cancer August 06, 2021Vol.47 No.31
Drugs & TargetsFree BMS issues statement on Istodax relapsed/refractory peripheral T-cell lymphoma U.S. indication August 06, 2021Vol.47 No.31
Drugs & TargetsFree Keytruda receives FDA approval for high-risk early-stage TNBC July 30, 2021Vol.47 No.30
